The medicine asciminib is showing promising results in the treatment of patients with chronic myeloid leukaemia (CML). Recently, Swiss pharma company Novartis presented results from a phase III trial which compares asciminib with bosutinib, a drug that is currently often used to treat CML patients. The trial focused on CML patients who had undergone two or more prior treatments with tyrosine kinase inhibitors (TKI).
Asciminib is an allosteric inibitor that specifically targets the ABL myristoyl pocket (STAMP). As a STAMP inhibitor, asciminib may help address tyrosine-kinase inhibitor (TKI)-resistance and intolerance in later treatment lines of CML, and it is being studied in several clinical trials in hopes of helping patients across multiple treatment lines of CML. Asciminib inhibits both the normal as mutted BCR-ABL1 protein, including the T315I mutation. Thus far the safety of asciminib in the treatment of Philadelphia chromosome positive CML (Ph+ CML) had not been investigated.
In the ASCEMBL phase III study, asciminib was shown after 24 weeks to have a better molecular response compared to bosutinib in patients with Ph+ CML, who had undergone two or more previous treatments with TKI. Consequently, Novartis has announced to submit asciminib to the EMA in order to obtain admission to the European markt. Meanwhile, the FDA in the USA has already stated that asciminib is eligible for a fast-track admission procedure.
Read the full press release from Novartis